Nika Pharmaceuticals, Inc. (NIKA) Markets Analysis and €8.5 Billion Projected Revenue
Nika Pharmaceuticals (OTCQB: NIKA) has presented revenue projections for its ITV-1 HIV treatment across multiple markets with exclusive distribution agreements. The company projects total revenue of approximately €8.5 billion, with the majority (€7.9 billion) coming from Nigeria. Additional markets include UAE, Ukraine, Iraq, Jordan, and Syria, where NIKA will charge €1,980 per set of ITV-1, with two sets required per treatment.
In Ukraine, which has 158,803 registered HIV patients, NIKA projects potential revenue of €628 million. The combined markets of UAE, Iraq, Jordan, and Syria, with approximately 7,100 HIV patients, are expected to generate €28.1 million in revenue. The company emphasizes its dual mission of pursuing profits while providing affordable, life-saving treatments in regions with limited access to HIV care.
Nika Pharmaceuticals (OTCQB: NIKA) ha presentato le proiezioni di fatturato per il suo trattamento contro l'HIV, ITV-1, in diversi mercati con accordi di distribuzione esclusiva. L'azienda prevede un fatturato totale di circa 8,5 miliardi di euro, di cui la maggior parte (7,9 miliardi di euro) proveniente dalla Nigeria. Altri mercati includono Emirati Arabi Uniti, Ucraina, Iraq, Giordania e Siria, dove NIKA applicherà un prezzo di 1.980 euro per set di ITV-1, con due set necessari per ogni trattamento.
In Ucraina, che conta 158.803 pazienti HIV registrati, NIKA stima un potenziale fatturato di 628 milioni di euro. I mercati combinati di Emirati Arabi Uniti, Iraq, Giordania e Siria, con circa 7.100 pazienti HIV, dovrebbero generare un fatturato di 28,1 milioni di euro. L'azienda sottolinea la sua duplice missione di perseguire profitti offrendo al contempo trattamenti salvavita a prezzi accessibili in regioni con accesso limitato alle cure per l'HIV.
Nika Pharmaceuticals (OTCQB: NIKA) ha presentado proyecciones de ingresos para su tratamiento contra el VIH ITV-1 en varios mercados con acuerdos exclusivos de distribución. La compañía proyecta ingresos totales de aproximadamente 8,5 mil millones de euros, con la mayoría (7,9 mil millones de euros) provenientes de Nigeria. Otros mercados incluyen Emiratos Árabes Unidos, Ucrania, Irak, Jordania y Siria, donde NIKA cobrará 1.980 euros por set de ITV-1, siendo necesarios dos sets por tratamiento.
En Ucrania, que cuenta con 158.803 pacientes registrados con VIH, NIKA proyecta ingresos potenciales de 628 millones de euros. Los mercados combinados de Emiratos Árabes Unidos, Irak, Jordania y Siria, con aproximadamente 7.100 pacientes con VIH, se espera que generen 28,1 millones de euros en ingresos. La compañía enfatiza su doble misión de buscar ganancias mientras proporciona tratamientos asequibles que salvan vidas en regiones con acceso limitado a la atención del VIH.
Nika Pharmaceuticals (OTCQB: NIKA)는 독점 유통 계약을 맺은 여러 시장에서 HIV 치료제 ITV-1의 매출 전망을 발표했습니다. 회사는 총 매출 약 85억 유로를 예상하며, 그 중 대부분인 79억 유로가 나이지리아에서 나올 것으로 예상합니다. 추가 시장으로는 UAE, 우크라이나, 이라크, 요르단, 시리아가 있으며, NIKA는 ITV-1 한 세트당 1,980유로를 부과하고, 치료당 두 세트가 필요합니다.
우크라이나에는 158,803명의 등록된 HIV 환자가 있으며, NIKA는 잠재 매출을 6억 2,800만 유로로 예상합니다. UAE, 이라크, 요르단, 시리아의 합산 시장은 약 7,100명의 HIV 환자가 있으며, 2,810만 유로의 매출을 창출할 것으로 기대됩니다. 회사는 HIV 치료 접근성이 제한된 지역에서 합리적인 가격의 생명을 구하는 치료제를 제공하면서 이익을 추구하는 이중 사명을 강조합니다.
Nika Pharmaceuticals (OTCQB : NIKA) a présenté des projections de revenus pour son traitement contre le VIH, ITV-1, sur plusieurs marchés avec des accords de distribution exclusifs. La société prévoit un chiffre d'affaires total d'environ 8,5 milliards d'euros, dont la majeure partie (7,9 milliards d'euros) provient du Nigeria. Les marchés supplémentaires incluent les Émirats arabes unis, l'Ukraine, l'Irak, la Jordanie et la Syrie, où NIKA facturera 1 980 euros par set d'ITV-1, avec deux sets nécessaires par traitement.
En Ukraine, qui compte 158 803 patients VIH enregistrés, NIKA projette un chiffre d'affaires potentiel de 628 millions d'euros. Les marchés combinés des Émirats arabes unis, de l'Irak, de la Jordanie et de la Syrie, avec environ 7 100 patients VIH, devraient générer 28,1 millions d'euros de revenus. La société souligne sa double mission : rechercher des profits tout en fournissant des traitements abordables et vitaux dans des régions où l'accès aux soins du VIH est limité.
Nika Pharmaceuticals (OTCQB: NIKA) hat Umsatzprognosen für seine HIV-Behandlung ITV-1 in mehreren Märkten mit exklusiven Vertriebsvereinbarungen vorgestellt. Das Unternehmen erwartet einen Gesamtumsatz von etwa 8,5 Milliarden Euro, wobei der Großteil (7,9 Milliarden Euro) aus Nigeria stammt. Weitere Märkte sind die VAE, die Ukraine, der Irak, Jordanien und Syrien, wo NIKA 1.980 Euro pro Set ITV-1 berechnet, wobei pro Behandlung zwei Sets erforderlich sind.
In der Ukraine, mit 158.803 registrierten HIV-Patienten, prognostiziert NIKA potenzielle Einnahmen von 628 Millionen Euro. Die kombinierten Märkte der VAE, des Irak, Jordaniens und Syriens mit etwa 7.100 HIV-Patienten sollen Einnahmen von 28,1 Millionen Euro generieren. Das Unternehmen betont seine doppelte Mission, Gewinne zu erzielen und gleichzeitig erschwingliche, lebensrettende Behandlungen in Regionen mit begrenztem Zugang zur HIV-Versorgung anzubieten.
- Significant revenue potential of €8.5 billion across all markets
- Strong market presence in Nigeria with €7.9 billion projected revenue
- Additional €628 million potential revenue from Ukrainian market
- Strategic expansion into multiple markets through exclusive distribution agreements
- Clear pricing structure at €1,980 per set with defined treatment protocol
- Heavy revenue dependency on Nigerian market (93% of total projections)
- Small patient population in UAE, Iraq, Jordan, and Syria (only 7,100 combined)
- Political instability and war in Ukraine could affect market access and distribution
- Revenue projections are estimates and may not materialize
HENDERSON, Nev., May 19, 2025 (GLOBE NEWSWIRE) -- Nika Pharmaceuticals, Inc. (OTCQB: NIKA) presents projected revenue for each market with exclusive distribution agreement.
NIKA has previously reported an estimated potential
The war in Ukraine has exacerbated the country’s issue with HIV due to low stocks of life-saving drugs and potential treatment disruption to nearly
“Although the markets of Ukraine, UAE, Jordan, Syria, and Iraq are not as big as Nigeria, our mission is to not only chase profits, but also provide better and affordable life-saving drugs to those who have their lives at risk as they would otherwise not have access to treatment,” explained Dimitar Savov, CEO of NIKA.
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements. Find more on www.nikapharmaceuticals.com.
Forward-looking Statement:
This press release contains forward-looking statements. Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “estimates,” “projects,” “intends,” “plan,” “can,” “will,” “would,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.
1 See https://www.globenewswire.com/news-release/2024/07/18/2915494/0/en/Nika-Pharmaceuticals-Inc-NIKA-Signed-a-Distribution-Agreement-for-Nigeria.html
2 Based on www.unaids.org estimates.
3 See https://pharmacophorejournal.com/e7AoOTeg1j
4 See https://www.unaids.org/en/War-Ukraine-special
5 See https://www.who.int/europe/news-room/19-12-2023-on-the-frontline-of-the-fight-against-hiv--ukraine-s-resilience-and-who-s-support#:~:text=In%20Ukraine%2C%20the%20Ministry%20of,Ukraine%20is%20currently%
CONTACT Clifford Redekop, Secretary COMPANY Nika Pharmaceuticals, Inc. PHONE (702)-326-3615 EMAIL info@nikapharmaceuticals.com WEB www.nikapharmaceuticals.com
FAQ
What is NIKA's projected total revenue across all markets?
How much does NIKA's ITV-1 HIV treatment cost per patient?
What is NIKA's projected revenue from the Ukrainian market?
How many HIV patients are in NIKA's Middle Eastern markets?
What percentage of NIKA's projected revenue comes from Nigeria?
